

6 March 2023



The Nifty ended 0.67% up at 17711.45. It opened on a positive note and touched days high, however, sell off in the last hour led to an inverted hammer on daily. Chart pattern suggesting, weakness likely to persist as long as it trades below 17800 levels. Hence, staying cautious on rise is advised. The Nifty immediate range likely to be 17550-17800 with a negative bias.

On the Nifty hourly chart, pullback against ongoing retracement may find sellers on rise around critical MA band placed around 17800 levels. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; weakness likely to sustain as long as it trades below 17800. Immediate range likely to be 17550-17800.

Nifty Crucial Supports & Resistances-

Supports- 17600, 17550 Resistances- 17800, 17900

Open Positional Calls-

T+15 SELL-

| Fut Segment | HINDALCO @ 420-425, TGT- 385, Closing SL- above 445

Key Contents	Page No.
Domestic News	8

Nifty Intraday Chart



Market in Retrospect

India's benchmark stock indices ended with gains for the second day on Monday, led by advances in I.T. and oil and gas stocks.

Nifty index ended 0.67% higher, ended at 17,711. The broader markets represented by the Nifty 500 Index ended 0.72% higher, ending at 14,881. Among the sectorial indices, Nifty Energy was the top gainer gaining by 1.93%, followed by Nifty PSE gaining by 1.67%. Nifty Realty was the top loser losing by 0.52%.

Adani Enterprises was the top gainer, gaining by 5.50%, followed by Tata Motors and ONGC which gaining by 2.83% & 2.56%. Britannia Industries was the top loser, losing by 2.09%, followed by Tata Steel and JSW Steel losing by 1.26% & 1.18%.

Market Turnover (In Crore) 06-03-2023

Name	Last	Previous
NSE Cash	52251.21	51166.65
NSE F&O	22386073.62	14437034.58
BSE Cash	3,283.80	3,430.47
BSE F&O	*NA	5.36

FII Derivatives Flow (In Crore) 06-03-2023

Instrument	Purchase	Sale	Net
Index Future	4055.09	2608.45	1446.64
Index Option	1429915.90	1430826.61	910.71
Stock Future	9054.94	9159.86	104.92
Stock Option	9402.46	9190.92	211.54

Institutional Flow (In Crore) 06-03-2023

Institution	Purchase	Sale	Net
FII	7035.15	6313.78	721.37
DII	5659.58	4902.35	757.23

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Adani Enterprises	5.50	66.14	27180456	22838710
Tata Motors	2.83	5.30	11307064	8274951
ONGC	2.56	1.90	14491522	10740060
NTPC	2.43	2.55	12402804	13344430
Power Grid Corp	2.27	3.63	11744968	23531910

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Indusind Bank	0.51	3.57	3623590	2921995
Hindalco Industries	0.58	0.66	5071598	7663659
JSW Steel	1.18	0.92	1215223	1474131
Tata Steel	1.26	0.42	106868143	76276900
Britannia Industries	2.09	1.56	681562	240467

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 6:30PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	60224.46	415.49	0.69	1.58	0.10	3.50	13.97
Nifty	17711.45	117.10	0.67	1.83	0.06	4.57	11.65
BSE M Cap	24773.55	177.66	0.72	3.17	0.58	5.47	9.53
BSE S Cap	28096.03	249.63	0.90	3.17	0.34	6.00	6.88
Nifty MC 100	30960.05	262.40	0.85	3.56	0.97	4.17	15.24
BSE Auto	29634.19	284.74	0.97	1.93	2.02	0.12	36.76
BSE Capgoods	34389.79	15.43	0.04	1.72	0.19	0.19	33.76
BSE FMCG	16436.33	80.21	0.49	1.47	1.37	0.30	29.05
BSE Metal	19644.25	102.90	0.52	1.01	2.56	4.96	10.12
BSE Oil&Gas	17633.46	328.75	1.90	2.77	0.18	13.91	1.28
BSE Healthcare	21778.56	86.40	0.40	0.12	1.96	8.09	4.84
BSE Power	3474.62	84.80	2.50	6.36	2.47	24.65	8.90
BSE Realty	3272.55	25.10	0.76	5.07	0.59	10.33	4.66
BSE ConsDur	38113.11	245.02	0.65	1.80	0.53	6.61	4.99
BSE Bank	46814.66	113.64	0.24	2.43	0.27	4.72	24.09
BSE IT	29905.56	364.42	1.23	0.86	1.10	1.86	11.24

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.91	0.04	0.94	0.02	7.55	10.85	126.19
UK	3.82	0.03	0.83	0.32	17.66	24.09	215.98
Brazil	6.60	0.05	0.74	0.50	8.50	16.34	32.62
Japan	0.51	0.00	0.00	0.20	0.20	97.66	210.43
Australia	3.77	0.14	3.49	2.81	8.78	10.87	75.12
India	7.41	0.01	0.11	0.15	1.16	2.18	8.67
Switzerland	1.54	0.01	0.71	4.12	17.65	52.48	805.88
Germany	2.67	0.04	1.62	3.45	16.33	48.39	3971.01

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	81.92	0.06	0.07	1.14	1.00	0.85	6.04
USD Index	104.61	0.09	0.09	0.06	0.96	0.91	6.05
YUAN	6.94	0.03	0.47	0.11	2.02	0.84	8.88
GBP	1.20	0.00	0.30	0.53	0.16	1.10	8.42
EUR	1.06	0.00	0.01	0.24	0.86	1.60	2.03
YEN	136.14	0.27	0.20	0.04	2.56	0.63	15.29

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1211.00	66.00	5.76	29.52	99.18	9.63	43.62
Baltic Dirty	1483.00	11.00	0.75	8.80	21.16	29.78	0.61
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	33390.97	387.40	1.17	1.75	1.48	0.61	0.67
Nasdaq	11689.01	226.03	1.97	2.58	1.67	6.12	12.20
S&P 500	4045.64	64.29	1.61	1.90	1.59	2.65	6.54
FTSE100	7903.79	43.67	0.55	0.40	0.85	5.08	13.11
CAC40	7358.29	10.30	0.14	0.86	3.10	10.03	21.39
DAX	15616.03	36.23	0.23	1.52	1.75	8.86	19.25
Mexico IPC	54182.27	852.74	1.60	2.84	0.25	6.20	1.61
Brazil Bovespa	103866.0	540.38	0.52	1.83	4.47	5.74	9.27
Russian RTS	956.63	11.10	1.17	1.19	5.03	12.81	2.09
Japan Nikkei	28237.78	310.31	1.11	2.97	1.99	1.99	11.96
Hang Seng	20603.19	35.65	0.17	3.31	3.27	9.51	2.16
Taiwan Index	15763.51	155.09	0.99	0.95	2.35	7.75	8.24
Shanghai Comp	3322.03	6.37	0.19	1.96	2.28	3.83	1.51
KOSPI	2462.62	30.55	1.26	1.61	0.45	3.35	7.12
Malaysia KLCI	1452.68	0.87	0.06	0.19	1.61	0.97	7.62
Jakarta Comp	6807.00	6.64	0.10	0.70	1.85	0.17	0.90
Philippine SE	6671.12	15.75	0.24	1.09	3.05	2.24	8.47
Thai Exch	1606.88	5.76	0.36	1.66	4.47	1.60	3.88

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	78.61	1.07	1.34	3.87	6.07	5.87	32.05
BRENT Crude	84.71	1.13	1.32	3.24	4.94	5.99	11.49
Natural Gas	2.68	0.33	10.83	1.76	5.84	40.65	26.77

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1850.94	5.69	0.31	1.85	0.89	4.50	6.08
Silver(\$/Ounce)	21.14	0.13	0.60	2.44	5.10	4.77	17.77
Aluminium	2361.00	5.75	0.24	3.33	6.85	6.21	36.85
Copper	8954.50	26.40	0.30	3.06	0.04	6.19	13.76
Zinc	3100.50	33.50	1.09	3.76	5.17	0.49	21.18
Lead	2117.50	5.50	0.26	1.91	1.60	3.30	11.95

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	176.90	0.95	0.53	5.12	0.63	7.80	18.44
Cotton	83.73	0.44	0.52	1.26	0.45	0.53	10.85
Sugar	20.74	0.18	0.86	2.22	6.36	13.46	13.58
Wheat	698.25	10.50	1.48	1.65	8.37	5.61	23.52
Soybean	1514.50	4.25	0.28	0.12	0.00	3.10	8.49

Hero MotoCorp to collaborate with Zero Motorcycle for premium electric motorcycles

The country's largest two-wheeler maker Hero MotoCorp have reached an agreement with California-based Zero Motorcycles to co-develop premium electric motorcycles. The companies intend to combine the expertise of Zero in developing power trains and electric motorcycles with the scale of manufacturing, sourcing and marketing of Hero MotoCorp through the collaboration.

Olectra bags order for 550 e-buses from Telangana State Road Transport Corporation

Olectra Greentech Limited, a subsidiary of Megha Engineering & Infrastructures Limited (MEIL), on Monday said it has received an order for 550 pure electric buses from the Telangana State Road Transport Corporation (TSRTC). A press release from the firm said it is the single largest order for electric buses in South India from TSRTC and is vital in Telangana's electric mobility step for large-scale clean, green public transportation. The order is to supply 50 standard floor 12-metre intercity coach e-buses and 500 low floor 12-metre intracity e-buses, K V Pradeep, chairman and managing director of Olectra Greentech Limited. The 50 intercity coach e-buses will ply between the city of pearls, Hyderabad in Telangana and Vijayawada in Andhra Pradesh. The e-buses are fully air-conditioned and can travel a distance of more than 325 km on a single charge. In the intracity segment, the 500 e-buses will ply within Hyderabad. Each e-bus can travel a distance of more than 225 km on a single charge.

NTPC logs nearly 12 percent growth in electricity generation in April-February this fiscal year

State-owned power giant NTPC on Monday said that it has logged nearly 12 per cent growth in electricity generation to 364.2 billion units in April-February period this fiscal compared to year ago. NTPC Ltd registered 11.92 per cent growth in generation i.e. 364.2 BU in FY23 till February month, compared to the country's generation growth of 9.56 per cent. NTPC continues to demonstrate an increasing trend in coal production from its captive mines. It stated that the NTPC Captive Coal production stood 2.6 Million Metric tonnes(MMT) whereas the despatch stood 2.5 MMT, thus registered a robust growth of 80 per per cent and 87 per cent respectively, in February vis-a-vis previous corresponding year. On a cumulative basis, the coal production crossed 20 MMT in FY23. NTPC has taken various steps to augment the coal production from its coal mines. The engagement of high-capacity dumpers as well as an increase in , it stated.

Alembic Pharma gets USFDA nod for generic cancer drug

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market a generic drug to treat cancer. The company has received approval from the US Food & Drug Administration (USFDA) for Fluorouracil Injection. The approved product is therapeutically equivalent to Spectrum Pharmaceuticals Inc's product. Fluorouracil injection is indicated for the treatment of patients with adenocarcinoma of colon and rectum, adenocarcinoma of the breast, gastric adenocarcinoma and pancreatic adenocarcinoma. According to IQVIA data, Fluorouracil Injection USP, 2.5 g/50 mL (50 mg/mL) vial, has an estimated market size of USD 5 million in the US market. Alembic said it now has a cumulative 182 abbreviated new drug application (ANDA) approvals from the USFDA.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
No events	

Domestic Events

- India Foreign Exchange Reserve for February 24, 2023.
- India S&P Services and Composite PMI for February 2023.

Global Events

- **7th March 2022:-** China Balance of Trade for January - February 2023., China Foreign Exchange Reserve for February 2023., Japan Foreign Exchange Reserve for February 2023., The U.S. Fed Chair Powell Testimony.
- **8th March 2022:-** Euro Area GDP for Q4 2022., The U.S. Balance of Trade for January 2023.

Analyst Certification:

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
